Jump to content
  • rrdiLogo384x64.jpg

    We are rosaceans and this is a grassroots rosacea non profit organization. Finding the Cure for rosacea. If you like to read, scroll down to the bottom. If you prefer videos, scroll down to view all the videos about the RRDi. What's with the butterfly? We need 100 Active Subscribers! To learn more about the RRDi watch the videos by scrolling below, or if you prefer reading, keep scrolling. If you want to change how the RRDi is run, why not volunteer to post (subscription fees waived for volunteers) and tell us what you think the RRDi should be doing. 

    Join the most private rosacea community on the web!

    Videos & RRDi Social Media Accounts

  • Forum Statistics

    • Total Topics
      6.5k
    • Total Posts
      8.2k
  • The Rosacea Research & Development Institute [RRDi] is the first 501 (c) (3) non profit organization approved by the IRS established June 7, 2004 in the State of Hawaii, USA for the purpose of finding a cure for rosacea, researching rosacea, and to form a rosacea patient advocacy organization established by volunteer rosaceans for rosacea sufferers. In December 2019 we have moved the corporate office to the State of Alabama and have registered as a non profit corporation.

    Our non profit organization for rosacea patient advocacy web site is a digital data repository of rosacea information that can serve you personally as an armamentarium of rosacea treatment options. We have tools to help you in your search for a cure to rosacea, or at least a way to control it.

    We have chosen the Invision Community as the chief digital platform tool (with beta versions for Android and iOS mobile apps) to use, a public platform for guests and inactive members. Our member forum is the most private forum for rosacea on the internet. We also have a private platform using Tapatalk using our rosacea-control.com domain. 

    We are rosacea sufferers [rosaceans] and all are volunteers. We rely on donations. No one is receiving a salary or getting paid. We don't spend donated funds on private contractors that are owned by any member of the board of directors. We do not spend donated funds so our members can attend dermatology conventions. All donations are spent on keeping this non profit organization for rosacea sufferers a viable patient advocacy organization and our rules state that 'members may not profit from the institute' (rule number 3). Read our mission statement

    No one has a paid salary, we pay NO private contractors nor do we use donations so our members can attend dermatology conventions. 

    All the other rosacea non profits are not run by rosacea sufferers (see Other Non Profit Rosacea Organizations on this page). Check out the other non profit organizations for rosacea, discover for yourself and you will find out who serve on the board of directors (non rosaceans - dermatologists/businessmen) and then simply follow the money (what does the organization spend most of the donated money on?) and discover for yourself that the other non profit organizations for rosacea spend most of the donations on (1) private contractors, (2) dermatologist member conventions or (3) salaries. We have no special interest other than finding the cure for rosacea and forming a rosacea patient advocacy organization. Our non profit has no salaries, no spending on private contractors, no expenses for member conventions. Follow the money (this is where we spend our money). Notice where most of the money is spent with another rosacea non profit, who has spent millions of dollars on private contractors owned by the president of the non profit and only 10% on rosacea research. 

    Read our Misson Statement and see if you agree? If you suffer from rosacea, this is the rosacea non profit to join. Your membership increases our impact on the medical community. Our goal is to reach 10,000 members. Please join and help us reach our goal. What if 10,000 members got together and each donated one dollar and all the members agreed we should sponsor a certain rosacea research study. Is this possible? Only with your help. 

    You may want to read our post about Anonymity, Transparency and Posting before joining. We have now switched to a subscription member service

    The logo of the RRDi includes a butterfly because rosacea typically manifests itself in a facial butterfly formation, however the irony of the butterfly effect is apropros. Learn More.

    You may want to learn about the history of this non profit or why it was formed

    If you are a rosacean, volunteer by joining our private member forum and posting or in our public guest forum (registration required) becoming a part of 'finding the cure' for rosacea if you join. Our goal is 10,000 members. Membership is free. You can help us reach our goal by joining with just your email address.  if privacy is of paramount importance to you use Sign in with Apple and join our private member forum. Or you can simply browse our web site and guest forum for free. Our non profit affiliate store is another source of rosacea treatment options. 

    If you want to post about your rosacea, we certainly allow you to post feedback in our GUEST forum or register an account in our member forum, i.e,, in our public community support, and, if you want to learn about and treat your rosacea, this is the best non profit organization for rosacea sufferers. At the social networks like Facebook, Instagram or Reddit can you find the incredible digital tools the RRDi provides free to its members or the ability to find what you are searching for in rosacea research? Are you able through such social media groups to influence the medical community how you feel about rosacea? Read our mission statement and compare with your private rosacea social media group, i.e., like Facebook, Instagram or Reddit.  

    The RRDi is registered at GuideStar and Trustpilot • Write a Review of Our Non Profit

  • Member Statistics

    1,676
    Total Members
    499
    Most Online
    Angela Serriteno
    Newest Member
    Angela Serriteno
    Joined


  • Registered with the USA Internal Revenue Service

    IRSlogo.png

    EIN 20-1259275

  • 240px-Seal_of_Alabama.svg.png

  • Alabama Secretary of State Certification

    Entity Identification Number 596-247

  • Guest Signup

    Show your support for the RRDi

  • Posts

    • Exp Dermatol. 2024 Apr;33(4):e15081. doi: 10.1111/exd.15081. ABSTRACT The close interaction between skin and clothing has become an attractive cornerstone for the development of therapeutic textiles able to alleviate skin disorders, namely those correlated to microbiota dysregulation. Skin microbiota imbalance is known in several skin diseases, including atopic dermatitis (AD), psoriasis, seborrheic dermatitis, rosacea, acne and hidradenitis suppurative (HS). Such microbiota dysregulation is usually correlated with inflammation, discomfort and pruritus. Although conventional treatments, that is, the administration of steroids and antibiotics, have shown some efficacy in treating and alleviating these symptoms, there are still disadvantages that need to be overcome. These include their long-term usage with side effects negatively impacting resident microbiota members, antibiotic resistance and the elevated rate of recurrence. Remarkably, therapeutic textiles as a non-pharmacological measure have emerged as a promising strategy to treat, alleviate the symptoms and control the severity of many skin diseases. This systematic review showcases for the first time the effects of therapeutic textiles on patients with skin dysbiosis, focusing on efficacy, safety, adverse effects and antimicrobial, antioxidant and anti-inflammatory properties. The main inclusion criteria were clinical trials performed in patients with skin dysbiosis who received treatment involving the use of therapeutic textiles. Although there are promising outcomes regarding clinical parameters, safety and adverse effects, there is still a lack of information about the impact of therapeutic textiles on the skin microbiota of such patients. Intensive investigation and corroboration with clinical trials are needed to strengthen, define and drive the real benefit and the ideal biomedical application of therapeutic textiles. PMID:38628046 | DOI:10.1111/exd.15081 {url} = URL to article
    • JAMA Dermatol. 2024 Apr 17. doi: 10.1001/jamadermatol.2024.0408. Online ahead of print. ABSTRACT IMPORTANCE: Treatment of erythema and flushing in rosacea is challenging. Calcitonin gene-related peptide (CGRP) has been associated with the pathogenesis of rosacea, raising the possibility that inhibition of the CGRP pathway might improve certain features of the disease. OBJECTIVE: To examine the effectiveness, tolerability, and safety of erenumab, an anti-CGRP-receptor monoclonal antibody, for the treatment of rosacea-associated erythema and flushing. DESIGN, SETTING, AND PARTICIPANTS: This single-center, open-label, single-group, nonrandomized controlled trial was conducted between June 9, 2020, and May 11, 2021. Eligible participants included adults with rosacea with at least 15 days of either moderate to severe erythema and/or moderate to extreme flushing. No concomitant rosacea treatment was allowed throughout the study period. Visits took place at the Danish Headache Center, Copenhagen University Hospital, Rigshospitalet in Copenhagen, Denmark. Participants received 140 mg of erenumab subcutaneously every 4 weeks for 12 weeks. A safety follow-up visit was performed at week 20. Data analysis occurred from January 2023 to January 2024. INTERVENTION: 140 mg of erenumab every 4 weeks for 12 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was mean change in the number of days with moderate to extreme flushing during weeks 9 through 12, compared with the 4-week run-in period (baseline). The mean change in number of days with moderate to severe erythema was a secondary outcome. Adverse events were recorded for participants who received at least 1 dose of erenumab. Differences in means were calculated with a paired t test. RESULTS: A total of 30 participants (mean [SD] age, 38.8 [13.1] years; 23 female [77%]; 7 male [23%]) were included, of whom 27 completed the 12-week study. The mean (SD) number of days with moderate to extreme flushing was reduced by -6.9 days (95% CI, -10.4 to -3.4 days; P < .001) from 23.6 (5.8) days at baseline. The mean (SD) number of days with moderate to severe erythema was reduced by -8.1 days (95% CI, -12.5 to -3.7 days; P < .001) from 15.2 (9.1) days at baseline. Adverse events included transient mild to moderate constipation (10 participants [33%]), transient worsening of flushing (4 participants [13%]), bloating (3 participants [10%]), and upper respiratory tract infections (3 participants [10%]), consistent with previous data. One participant discontinued the study due to a serious adverse event (hospital admission due to gallstones deemed unrelated to the study), and 2 participants withdrew consent due to lack of time. CONCLUSIONS AND RELEVANCE: These findings suggest that erenumab might be effective in reducing rosacea-associated flushing and chronic erythema (participants generally tolerated the treatment well, which was consistent with previous data), and that CGRP-receptor inhibition holds potential in the treatment of erythema and flushing associated with rosacea. Larger randomized clinical trials are needed to confirm this finding. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04419259. PMID:38630457 | DOI:10.1001/jamadermatol.2024.0408 {url} = URL to article
    • JAMA Dermatol. 2024 Apr 17. doi: 10.1001/jamadermatol.2024.0397. Online ahead of print. NO ABSTRACT PMID:38630466 | DOI:10.1001/jamadermatol.2024.0397 {url} = URL to article
    • J Cutan Pathol. 2024 Apr 13. doi: 10.1111/cup.14623. Online ahead of print. ABSTRACT Seborrheic dermatitis is an inflammatory condition that usually presents with erythema, scaly greasy papules, and plaques affecting sebaceous gland-rich areas and predominantly involving the face and scalp. The diagnosis of seborrheic dermatitis can often be rendered based on the clinical presentation. However, in certain cases, a biopsy can be useful to distinguish it from clinical mimics such as psoriasis, discoid lupus, and rosacea. Prominent sebaceous gland atrophy without scarring has been well-described as an important and relatively specific clue for psoriatic or drug-induced alopecia. However, sebaceous gland atrophy is not specific to psoriasis and has been demonstrated in seborrheic dermatitis, facial discoid dermatitis, and potentially may occur in other inflammatory dermatoses of the scalp. We report a 23-year-old female patient presenting with non-scarring hair loss and histopathological findings demonstrating mild androgenetic alopecia and changes of seborrheic dermatitis with dramatic sebaceous gland atrophy. The patient had no history or evidence of psoriasis clinically. Our case suggests that in patients with seborrheic dermatitis, sebaceous gland atrophy may complicate the evaluation of alopecia biopsies and should be recognized as a pitfall. Seborrheic dermatitis should be included in the differential diagnosis of alopecia biopsies showing prominent sebaceous gland atrophy. PMID:38613429 | DOI:10.1111/cup.14623 {url} = URL to article
    • An Bras Dermatol. 2024 Apr 12:S0365-0596(24)00037-0. doi: 10.1016/j.abd.2023.07.005. Online ahead of print. ABSTRACT OBJECTIVE: To evaluate the effects of rosacea on ocular surface changes such as alterations in dry eye parameters, corneal densitometry, and aberrations, in comparison with healthy controls. METHODS: A total of 88 eyes of 44 patients diagnosed with rosacea and 88 eyes of 44 healthy controls were enrolled in this cross-sectional study. All participants underwent a comprehensive dermatologic and ophthalmic examination and Tear Break-Up Time (TBUT) and Schirmer-1 tests were performed. The rosacea subtype and Demodex count and OSDI scores of all participants were recorded. Corneal topographic, densitometric, and aberrometric measurements were obtained using the Scheimpflug imaging system. RESULTS: The mean age of the 44 patients was 41.2 ± 11.0 years of whom 31 (70.5%) were female. The mean TBUT and Schirmer-1 test values were significantly decreased and OSDI scores were significantly increased in the rosacea group compared to healthy controls (p < 0.01 for all). The most common subtype of rosacea was erythematotelangiectatic rosacea (70.4%). The severity grading of rosacea revealed that 18 (40.9%) patients had moderate erythema. The median (min-max) Demodex count was 14.0 (0-120) and the disease duration was 24.0 (5-360) months. The comparison of the corneal densitometry values revealed that the densitometry measurements in all concentric zones, especially in central and posterior zones were higher in rosacea patients. Corneal aberrometric values in the posterior surface were also lower in the rosacea group compared to healthy controls. The topographic anterior chamber values were significantly lower in the rosacea group. STUDY LIMITATIONS: Relatively small sample size, variable time interval to hospital admission, and lack of follow-up data are among the limitations of the study. Future studies with larger sample sizes may also enlighten the mechanisms of controversial anterior segment findings by evaluating rosacea patients who have uveitis and those who do not. CONCLUSION: Given the fact that ocular signs may precede cutaneous disease, rosacea is frequently underrecognized by ophthalmologists. Therefore, a comprehensive examination of the ocular surface and assessment of the anterior segment is essential. The main priority of the ophthalmologist is to treat meibomian gland dysfunction and Demodex infection to prevent undesired ocular outcomes. PMID:38614939 | DOI:10.1016/j.abd.2023.07.005 {url} = URL to article
    • Cureus. 2024 Mar 12;16(3):e56025. doi: 10.7759/cureus.56025. eCollection 2024 Mar. ABSTRACT Ivermectin was first discovered in the 1970s by Japanese microbiologist Satoshi Omura and Irish parasitologist William C. Campbell. Ivermectin has become a versatile pharmaceutical over the past 50 years. Ivermectin is a derivative of avermectin originally used to treat parasitic infections. Emerging literature has suggested that its role goes beyond this and may help treat inflammatory conditions, viral infections, and cancers. Ivermectin's anti-parasitic, anti-inflammatory, anti-viral, and anticancer effects were explored. Its traditional mechanism of action in parasitic diseases, such as scabies and malaria, rests on its ability to interfere with the glutamate-gated chloride channels in invertebrates and the lack of P-glycoprotein in many parasites. More recently, it has been discovered that the ability of ivermectin to block the nuclear factor kappa-light-chain enhancer of the activated B (NF-κB) pathway that modulates the expression and production of proinflammatory cytokines is implicated in its role as an anti-inflammatory agent to treat rosacea. Ivermectin has also been evaluated for treating infections caused by viruses, such as SARS-CoV-2 and adenoviruses, through inhibition of viral protein transportation and acting on the importin α/β1 interface. It has also been suggested that ivermectin can inhibit the proliferation of tumorigenic cells through various pathways that lead to the management of certain cancers. The review aimed to evaluate its multifaceted effects and potential clinical applications beyond its traditional use as an anthelmintic agent. PMID:38606261 | PMC:PMC11008553 | DOI:10.7759/cureus.56025 {url} = URL to article
    • J Cosmet Dermatol. 2024 Apr 10. doi: 10.1111/jocd.16300. Online ahead of print. ABSTRACT BACKGROUND: Pulsed-dye lasers (PDL) are one of the standard therapies for rosacea, but alternatives are needed. AIMS: To compare the efficacy and safety of the variable-sequenced, large-spot 532 nm KTP laser to the 595 nm PDL in treating rosacea. MATERIALS AND METHODS: A prospective, controlled, evaluator-blinded study. Patients were treated with either a KTP or PDL with 1-3 sessions at intervals of 6-8 weeks. A follow-up visit was scheduled on Week 6 post-treatment. Clinical outcome was assessed by computer-assisted analysis and by patients and two blinded dermatologists. Pain intensity during treatment and adverse events were documented. RESULTS: Forty-five patients (mean age 51 years) were allocated in a 2:1 ratio to either the KTP or PDL. Erythema in both treatment arms decreased significantly (p < 0.01). Clinical evaluation revealed high improvement. Mean pain intensity was significantly lower with the KTP (2.5/10) than with the PDL (4.1/10). Both lasers showed a good safety profile. Relevant purpura was only seen in the PDL group. CONCLUSIONS: Both the variable-sequenced, large-spot KTP and the PDL demonstrated comparable efficacy in treatment of rosacea. Regarding safety, the KTP exhibited fewer post-treatment reactions. The KTP might serve as a potential alternative to PDL in the treatment of rosacea. PMID:38600654 | DOI:10.1111/jocd.16300 {url} = URL to article
    • Dermatol Surg. 2024 Apr 9. doi: 10.1097/DSS.0000000000004192. Online ahead of print. NO ABSTRACT PMID:38595166 | DOI:10.1097/DSS.0000000000004192 {url} = URL to article
    • J Am Acad Dermatol. 2024 Apr 7:S0190-9622(24)00571-1. doi: 10.1016/j.jaad.2024.03.042. Online ahead of print. NO ABSTRACT PMID:38593974 | DOI:10.1016/j.jaad.2024.03.042 {url} = URL to article
×
×
  • Create New...

Important Information

Terms of Use